# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-30T16:44:54.778832

---

**Idea Fidelity**

The paper closely adheres to the idea manifest. It exploits the staggered rollout of Seguro Popular (2002–2005 cohorts) using municipality-level INEGI death microdata (1998–2012) and complements aggregate infant/neonatal mortality with a cause-specific decomposition into amenable versus non-amenable ICD-10 categories, exactly as proposed. The Callaway–Sant’Anna staggered DiD estimator with not-yet-treated controls is the centerpiece of the empirical strategy, conditional on baseline municipal covariates, and the paper emphasizes the non-amenable category as a built-in placebo. The planned robustness checks and discussion of measurement challenges (denominator construction, pilot states) are reflected in the submitted manuscript. No key element from the manifest is missing.

---

**Summary**

The paper evaluates whether Mexico’s Seguro Popular reduced cause-specific infant mortality by applying a Callaway–Sant’Anna staggered DiD estimator to 1,404 municipalities observed from 1998 to 2012, leveraging administrative death microdata to decompose infant deaths into amenable and non-amenable causes. The main finding is a suggestive (but imprecise) decline in amenable infant mortality—primarily perinatal deaths—while non-amenable causes remain stable, which the authors interpret as consistent with improved healthcare access rather than confounding trends. Aggregate infant mortality remains statistically unchanged, underscoring the importance of the cause-based decomposition.

---

**Essential Points**

1. **Precision and Power – Are the estimates informative?** The key policy claim rests on a negative point estimate for amenable mortality ($-0.269$) that is statistically indistinguishable from zero, with wide confidence intervals that cover substantively meaningful magnitudes as well as null effects. Given the limited number of clusters (32 states) and the small magnitudes, the paper needs to provide a clearer sense of statistical power (or the lack thereof) for the main comparison. In particular, how large would the amenable mortality effect have to be to be detectable with the available data? Presenting minimum detectable effects or reporting honest DiD sensitivity bounds would help the reader assess whether the suggestive result is credible or is simply noise.

2. **Denominator Construction and Validity of Rates** – The denominator for municipal birth counts is derived indirectly by scaling total deaths with national crude death/birth rates, which relies on the assumption that municipal mortality and natality ratios follow national patterns. This raises concerns about potential non-random measurement error, especially if the degree of underreporting differs by municipal characteristics correlated with treatment timing. While the authors argue the error is classical and absorbed by fixed effects, there is a risk that enrollment timing is correlated with the direction of measurement error (e.g., poorer municipalities with higher under-registration entering earlier). Please provide more diagnostics: how do the estimated births compare to later SINAC counts (2008 onward) for the overlapping years? Does the measurement error change over time or across cohorts? Without these diagnostics, it is hard to assess whether the attenuation bias undermines the inference.

3. **Parallel Trends Assumption and Placebo Strength** – The credibility of the causal estimates hinges on conditional parallel trends, yet the paper does not present formal event-study graphs for amenable versus non-amenable mortality or report placebo pre-trend tests. Instead, the placebo is interpreted as the zero post-treatment effect on non-amenable causes. I suggest adding event-study plots with confidence bands for each cause category (amenable, non-amenable, perinatal, etc.) and reporting pre-treatment coefficients and joint tests. This would demonstrate whether the treated and control municipalities were trending similarly before SP, which is essential even if the non-amenable post-period coefficients are null. The current robustness checks (e.g., excluding pilot states) are useful but insufficient to convince the reader of the parallel trend assumption.

If further essential issues remained (e.g., large violations of assumptions), the paper would need more substantial revisions, but these three points already demand attention before publication.

---

**Suggestions**

1. **Clarify Aggregation Logic and Interpretation** – The paper argues that aggregate IMR is null because the amenable reductions are diluted by non-amenable deaths. It would strengthen the empirical narrative to present a decomposition of the overall AMR into amenable and non-amenable components over time (e.g., stacked area chart). This would illustrate how much weight each component has in the aggregate and why a modest amenable decline would be masked. Additionally, clarify whether the implied perinatal effect ($-0.301$) is large relative to the variation in pre-treatment perinatal mortality—expressing the effect as a percent change or in SDE units (already in Appendix C) could help.

2. **Explore Heterogeneity by Municipal Characteristics** – Given the policy variation in SP rollout driven by poverty and infrastructure, the paper could explore heterogeneity across municipal poverty (marginality index), urban/rural status, or baseline maternal care access. For example, does the amenable mortality effect differ between municipalities with high versus low clinic density, or between those with high indigenous population shares? While the main analysis controls for such covariates, heterogeneity analysis would provide insight into mechanisms and policy targeting.

3. **Strengthen Mechanism Evidence** – The paper posits that perinatal conditions decline due to improved prenatal care and institutional delivery. Although the data appendix hints at potential sources (ENSANUT, CLUES), the main text does not present mechanism evidence. Including a brief section (even if limited) that shows whether institutional delivery rates, prenatal visits, or facility availability changed faster in treated municipalities would considerably bolster the causal story. Alternatively, referencing existing studies (e.g., Barham et al.) is helpful, but direct evidence within the same sample would be more convincing.

4. **Address Potential Migration and SUTVA Concerns** – Insurance coverage at the municipal level may induce cross-border health-seeking behavior, especially if early adopter municipalities border later adopter states. While the paper states limited cross-border care, it would be helpful to provide empirical checks—such as placebo tests on neighboring municipalities or by excluding boundary areas—to support this assumption.

5. **Explicitly Report Weighting and Cohort-specific Effects** – The paper mentions Callaway–Sant’Anna but reports only aggregate ATTs. Including cohort-specific ATTs (e.g., separate estimates for the 2002, 2003, etc., cohorts) and the weights used by the estimator would increase transparency. If the early cohorts (pilot states) drive the overall effect, while later cohorts are null, this has implications for generalizability.

6. **Discuss External Validity of Amenable vs. Non-Amenable Classification** – The ICD-10 classification of amenable versus non-amenable deaths is central to the argument. Consider including a table or appendix that lists which ICD codes fall into each category and justify why certain conditions are treated as amenable. Some congenital anomalies may be partially treatable; clarifying the criteria for non-amenability and whether alternative categorizations (e.g., excluding ambiguous codes) change results would assuage concerns about misclassification.

7. **Interpretation of Null Findings** – Since the main amenable mortality estimate is imprecise, the policy takeaway should be cautious. Instead of implying SP “saved infants,” frame the result as pointing toward a potential but not definitive improvement. Emphasize that the cause decomposition reveals the direction of the effect, even if statistical significance is lacking, and highlight the importance of precision in future work.

Implementing these suggestions will enhance the credibility, transparency, and policy relevance of a promising empirical contribution.
